DiaMedica Therapeutics Inc.

DMAC Nasdaq SEC CIK 1401040
Follow DiaMedica Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$11.3M −31.2% vs same quarter last year
EPS, diluted −$0.21 −23.5% vs same quarter last year
Operating cash flow −$8.8M −34.8% vs same quarter last year
Operating income −$11.6M −28.7% vs same quarter last year
Net income by quarter
−$7.9M
−$7.7M
−$7.7M
−$8.6M
−$8.7M
−$10M
−$10.1M
−$11.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
−$40M−$30M−$20M−$10M$0FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$32.8M
FY24−$24.4M
FY23−$19.4M
FY22−$13.7M
FY21−$13.6M
FY20−$12.3M
FY19−$10.6M
FY18−$5.7M
FY17−$4.3M
FY16-
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$29.1M
FY24−$22.1M
FY23−$18.8M
FY22−$11.6M
FY21−$12.3M
FY20−$9.2M
FY19−$9.1M
FY18−$5.7M
FY17−$3.9M
FY16-